Lineage Cell Therapeutics, Inc.

LCTX | $1.15 -4.17% 0.0% 1.1M

(0.0% 1d) (5.7% 1m) (-8.5% 1y) (0.0% 2d) (0.0% 3d) (3.2% 7d) (202.25% volume)
Earnings Calendar:
Market Cap: $ 216,813,566
http://www.lineagecell.com
Sec Filling | Patents | 55 employees

(US) Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Alameda, CA.

hydrogen cancer stem cell t-cell drug delivery diagnostics neurological 3d msa ceiling

add to watch list Paper trade email alert is off

Press-releases

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium
Published: 2024-03-18 (Crawled : 16:00) - biospace.com/
ERNA | $2.16 0.47% 0.46% 3.7K

Information

| -0.92% | O: -0.92% H: 9.26% C: 8.8%
LCTX | $1.15 -4.17% 0.0% 1.1M

Health Technology

| 0.0% | O: -3.88% H: 1.61% C: -5.65%
symposium cell therapeutics

RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
Published: 2024-03-13 (Crawled : 13:00) - biospace.com/
ERNA | $2.16 0.47% 0.46% 3.7K

Information

| -11.48% | O: 4.1% H: 0.0% C: -11.81%
LCTX | $1.15 -4.17% 0.0% 1.1M

Health Technology

| 4.03% | O: 1.61% H: 2.38% C: -3.97%
rg6501 opregen innovation cell therapy results study

RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting
Published: 2024-03-11 (Crawled : 17:00) - biospace.com/
ERNA | $2.16 0.47% 0.46% 3.7K

Information

| -2.45% | O: 1.17% H: 10.27% C: 10.27%
LCTX | $1.15 -4.17% 0.0% 1.1M

Health Technology

| -0.77% | O: -5.38% H: 17.89% C: 4.88%
rg6501 opregen association research preclinical vision meeting results

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Published: 2024-03-07 (Crawled : 23:00) - biospace.com/
ERNA | $2.16 0.47% 0.46% 3.7K

Information

| 11.41% | O: 3.16% H: 0.0% C: -0.5%
LCTX | $1.15 -4.17% 0.0% 1.1M

Health Technology

| 14.16% | O: 1.77% H: 0.0% C: -1.74%
business year update cell therapeutics financial results

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024
Published: 2024-02-29 (Crawled : 15:00) - biospace.com/
LCTX | $1.15 -4.17% 0.0% 1.1M

Health Technology

| 24.04% | O: 1.92% H: 1.89% C: -1.89%
report business year update cell therapeutics financial results

Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury
Published: 2024-02-13 (Crawled : 14:00) - biospace.com/
LCTX | $1.15 -4.17% 0.0% 1.1M

Health Technology

| 19.44% | O: 1.85% H: 0.83% C: -7.27%
fda cell treatment clearance

Lineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering
Published: 2024-02-09 (Crawled : 15:30) - biospace.com/
LCTX | $1.15 -4.17% 0.0% 1.1M

Health Technology

| 19.44% | O: 5.56% H: 0.88% C: -5.26%
million direct cell offering therapeutics

Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering
Published: 2024-02-06 (Crawled : 15:00) - biospace.com/
LCTX | $1.15 -4.17% 0.0% 1.1M

Health Technology

| 24.04% | O: 2.88% H: 7.48% C: 3.74%
million direct cell offering therapeutics

Lineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury
Published: 2023-12-18 (Crawled : 14:00) - biospace.com/
LCTX | $1.15 -4.17% 0.0% 1.1M

Health Technology

| 41.74% | O: 1.66% H: 17.81% C: 14.57%
drug treatment submission

Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
Published: 2023-11-09 (Crawled : 00:00) - biospace.com/
LCTX | $1.15 -4.17% 0.0% 1.1M

Health Technology

| 17.27% | O: 0.91% H: 2.69% C: -3.6%
business update cell therapeutics financial results

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001493152-24-005944	4	2024-02-13	2024-02-11	Sell	M	6076	12151
0001493152-24-005944	4	2024-02-13	2024-02-11	Sell	F	2490	7184
0001493152-24-005944	4	2024-02-13	2024-02-11	Buy	M	6076	9674
0001493152-24-005942	4	2024-02-13	2024-02-11	Sell	M	31249	62499
0001493152-24-005942	4	2024-02-13	2024-02-11	Sell	F	12806	144842
0001493152-24-005942	4	2024-02-13	2024-02-11	Buy	M	31249	157648
0000919574-24-000757	4	2024-02-08	2024-02-06	Buy	P	6730770	41666255